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Influence of Diabetes Mellitus on Surgical 
Outcomes in Patients with Cervical Myelopathy: A 
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Study Design: Multicenter, prospective study.
Purpose: To investigate the effects of diabetes mellitus (DM) on surgical outcomes in patients with cervical myelopathy.
Overview of Literature: To date, few studies have investigated the influence of postoperative blood glucose or glycated hemoglobin 
(HbA1c) levels on surgical outcomes.
Methods: The participants were patients who underwent surgery for the treatment of cervical spondylotic myelopathy and ossifica-
tion of the posterior longitudinal ligament. The 61 cases were evaluated preoperatively and 1 year postoperatively using the Japanese 
Orthopaedic Association (JOA) scores and the JOA Cervical Myelopathy Evaluation Questionnaire (JOACMEQ). The study variables 
included fasting blood glucose and HbA1c levels measured preoperatively and at 1 week, 4 weeks, and 1 year postoperatively; the 
F-wave conduction velocity, latency, rate of occurrence, and M-wave latency in the ulnar and tibial nerves were measured preopera-
tively and at 1 year postoperatively. The patients were divided into a group without diabetes (N group, 42 patients) and a group with 
diabetes (DM group, 19 patients). We then assessed the associations between the surgical outcomes and each of the study variables.
Results: JOA scores significantly improved in both groups; however, no significant between-group differences were found. There 
was no significant improvement in the JOACMEQ scores, which assessed cervical function, upper and lower limb function, and blad-
der function in both groups. We then subdivided the DM group into those with a good control of HbA1c after 1 year (DMG group, 12 
patients) and those with HbA1c deterioration after 1 year (DMB group, seven patients), prior to comparing the surgical outcomes. The 
JOACMEQ scores for upper and lower limb function significantly improved in the DMG group (p<0.01). Compared with the DMB group, 
there were no significant increases in upper or lower limb function scores in the DMG group.
Conclusions: Poor glycemic control might prevent postoperative functional recovery of the spinal cord.
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Introduction
Cervical spondylotic myelopathy (CSM) is generally ob-
served in adults aged >50 years [1,2]. Common symptoms 
include numbness in the upper extremities (UE) and 
lower extremities (LE), bilateral impairments in dexterity, 
spastic gait disturbances, and bladder and bowel dysfunc-
tion. Treatment for CSM is well established; however, 
there are several risk factors for poor surgical outcomes. 
A previous study reported that the prevalence of diabetes 
mellitus (DM), hypertension, hyperlipidemia, and the use 
of anticoagulant and/or antiplatelet agents could affect 
cervical laminoplasty outcomes [3]. Associations between 
DM and surgical outcomes in patients with CSM have 
been reported in several recent publications [3-6].
Dokai et al. [5] has reported that patients with DM and 
CSM exhibited a poorer recovery of sensory function in 
the LE and an overall poorer recovery ratio (RR). Further-
more, Nakanishi has proposed that disruptions in micro-
vascular structures that result from DM influence CSM 
outcomes [7].
DM is a frequent comorbidity that affects many organs 
and causes numbness and weakness in the extremities 
due to peripheral nerve damage. The effects of DM on the 
peripheral nervous system and microvasculature are of 
concern.
Surgeons must consider issues surrounding DM control 
during the perioperative period. Previous reports have 
indicated that preoperative glycated hemoglobin (HbA1c) 
and blood sugar levels affect surgical outcomes in patients 
with CSM. However, few studies have examined the influ-
ence of postoperative blood glucose or HbA1c levels on 
surgical outcomes. Our study investigated the effects of 
DM on surgical outcomes in patients with CSM by assess-
ing DM control postoperatively.
Materials and Methods
We performed a prospective multicenter study at Tottori 
University Hospital, comprising eight hospitals in and 
around the Tottori Prefecture in Japan from 2012 to 2015.
Informed consent was obtained from all participants. 
Inclusion criteria were patients who underwent surgical 
treatments for CSM and ossification of the posterior lon-
gitudinal ligament. We used magnetic resonance imaging 
(MRI) to determine the compression level and regarded 
the compression level with cord intensity change at T2WI. 
If cord intensity changes were never determined, we con-
sidered the level of most severe stenosis within the cervi-
cal spine as the origin of the myelopathy.
All the patients underwent laminoplasty or anterior 
decompression and fusion at the discretion of the spinal 
surgeon at each institution. Exclusion criteria were (1) past 
history of cervical spine surgery; (2) congenital deformity 
of the cervical spine; (3) infection; (4) trauma; (5) tumor; 
(6) rheumatoid arthritis; (7) cervical palsy; (8) pacemaker 
treatment; and (9) paralysis without cervical disorder. The 
patients were divided into two groups: a group without 
diabetes (N group) and a group with diabetes (DM group). 
DM was diagnosed if any or all the following criteria were 
met, as defined by the Japan Diabetes Society: (1) fasting 
blood sugar >126 mg/dL, (2) causal blood sugar over 200 
mg/dL; (3) blood sugar over 200 mg/dL under 2 hours 75 g, 
and oral glucose-tolerance test; and (4) HbA1c over 6.5%.
The patients diagnosed with diabetic mellitus were treat-
ed with intensive blood sugar control by a doctor of inter-
nal medicine during the perioperative period. This study 
was approved by the local ethics committee of the Faculty 
of Medicine, Tottori University (IRB approval no., 1824). 
1. Surgical outcomes
The Japanese Orthopaedic Association (JOA) [8] and the 
Japanese Orthopaedic Association Cervical Myelopathy 
Evaluation Questionnaire (JOACMEQ) [9] scores were 
obtained to measure surgical outcomes preoperatively and 
at 1 year postoperatively. We calculated the RR as follows 
[10]: RR (%)=(postoperative JOA score−preoperative JOA 
score)/{17 (fullmark)−preoperative JOA score}×100.
2. Patient characteristics
Patient characteristics recorded included sex, age, height, 
weight, body mass index, and disease duration.
3. Diabetes mellitus
We evaluated fasting blood glucose (FBG) and HbA1c 
levels via routine blood testing preoperatively and 1 week, 
4 weeks, and 1 year postoperatively.
4. Electrophysiological evaluation
M- and F-waves were recorded from the ulnar and tibial 
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nerves. Surface recording electrodes were placed bilater-
ally on the abductor digiti minimi and abductor hallucis 
muscles. Stimulations were delivered from the proximal 
elbow to the ulnar nerve and from the popliteus to the 
tibial nerve. The peripheral conduction time (PCT) was 
calculated using Kimura’s method [11]. The PCT, exclud-
ing the turnaround time at the spinal motor neuron (1 
ms), was calculated from the compound muscle action 
potential and F-waves as follows: (M-wave latency+F-
wave latency−1)/2.
These assessments were performed preoperatively and 1 
year postoperatively.
5. Statistical analysis
All the data are expressed as mean±standard deviation. 
The statistical analyses were performed using StatMate 
ver. 5.0 for Windows and Mac (ATMS Co., Tokyo, Japan). 
Differences between groups were determined using Pear-
son’s chi-square test, Fisher’s exact test, and the Mann–
Whitney U-test. We performed Fisher’s exact test when 
the expected cell size was <5. The Mann–Whitney U-test 
was used for comparing JOA scores between groups. We 
compared PCT data between the two groups using Welch’s 
t-test.
Between-group differences in FBG and HbA1c levels 
were compared using paired t-tests. Correlations between 
the RR of the JOA score and FBG and HbA1c levels were 
estimated using the Pearson correlation coefficient (r). 
The Mann–Whitney U-test was used to compare JOA 
scores between the groups. After excluding patients whose 
pretreatment and post-treatment scores were ≥90 points 
from the analysis according to a previous report on the 
JOABPEQ [9], the Wilcoxon signed-rank test was used 
to determine categorical changes within the JOACMEQ 
scores in each group. The results were considered to be 
significant when p<0.05.
Table 1. Patient characteristics and demographics
Characteristic N group DM group p-value
Age (yr)     69.6±13.3   69.3±10.7 0.78a)
Gender (male:female)     25:11   12:17 0.79b)
Height (cm) 158.5±9.6 160.7±10.2 0.43
Weight (kg)     57.6±12.2   60.1±11.7 0.28
Body mass index (kg/m2)   22.8±3.4 23.2±3.7 0.72a)
CSM:OPLL     29:13 14:5 0.71b)
Peripheral conduction time (ms)
Ulna (right)   15.3±2.3 17.4±6.2 0.05a)
Ulna (left)   15.5±2.7 17.3±5.2 0.08a)
Tibia (right)   25.6±2.9 27.1±3.0 0.09a)
Tibia (left)   25.6±3.1 26.8±3.0 0.14a)
JOA score (total)   10.9±2.8 10.8±7.5 0.80a)
JOACMEQ
Cervical     70.5±30.7   62.6±30.2 0.37
Upper extremity     66.7±23.7   72.4±18.2 0.47
Lower extremity     52.3±31.7   52.3±26.4 0.91
Bowe & bladder     68.9±19.2   71.7±16.1 0.98
Quality of life     45.3±16.0   38.6±18.9 0.15
Values are presented as mean±standard deviation or number. No variables significantly differed between the groups (a group without diabetes [N 
group] and a group with diabetes [DM group]).
DM, diabetes mellitus; CSM, cervical spondylotic myelopathy; OPLL, ossification of the posterior longitudinal ligament; JOA, Japanese Orthopaedic 
Association; JOACMEQ, JOA Cervical Myelopathy Evaluation Questionnaire.
a)By Mann-Whitney U-test. b)By chi-square test.
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Results
1. Patients
A total of 148 participants were registered. A total of 140 
patients were included during the 3-year study period. 
Seventy-nine of these patients were excluded: 66 for miss-
ing values at the 1-year follow-up, two patients died, two 
patients suffered from lumbar spinal stenosis, two patients 
had spinal injuries, one patient had cerebrovascular dis-
ease, one patient was diagnosed with bile duct cancer, 
one patient was diagnosed with a vitamin B12 deficiency 
postoperatively, and four patients failed to present for the 
1-year follow-up appointment, resulting in 61 evaluable 
patients. The patients were then divided into two groups: a 
group without diabetes (N group, 42 patients) and a group 
with diabetes (DM group, 19 patients). The characteristics 
of the N and DM groups are presented in Table 1. There 
were no significant between-group differences.
We also divided the DM group into two subgroups ac-
cording to HbA1c levels over the preoperative period and 
the levels at the 1-year follow-up, in order to investigate 
the effects of HbA1c levels on surgical outcomes. The 
DMG group (n=12) consisted of individuals with good 
DM control at the 1-year follow-up. The DMB group (n=7) 
consisted of patients with DM control deteriorations at 
the 1-year follow-up (Fig. 1).
2.  Diabetes mellitus control from the preoperative pe-
riod until the 1-year follow-up
FBG and HbA1c level changes are shown in Table 2. In 
the N group, FBG levels significantly decreased at 1 week 
compared with the preoperative value. FBG levels at post-
operative week 4 and at 1 year did not significantly change 
relative to the preoperative values. HbA1c levels did not 
significantly change between the preoperative and postop-
erative visits. Although FBG levels significantly improved 
at 1 and 4 weeks postoperatively, FBG levels at 1 year 
postoperatively were not significantly different from the 
preoperative values. The HbA1c levels were significantly 
decreased only at 4 weeks postoperatively.
3.  Surgical outcomes based on the Japanese Orthopaedic 
Association scores
JOA scores significantly improved in both groups postop-
eratively (N group, p<0.01 and DM group, p=0.01). The 
RR was 40.1 in the N group and 26.3% in the DM group; 
between-group differences were not significant (Table 3).
4.  Correlations between glycated hemoglobin and re-
covery ratio
To determine whether reduced HbA1c levels correlated 
with surgical outcomes, we analyzed the relationship be-
tween HbA1c levels and RR in all cases. There was no cor-
relation throughout the study period (Table 4).
5.  Surgical outcomes based on the Japanese Orthopaedic 
Association Cervical Myelopathy Evaluation Ques-
tionnaire  scores
The surgical outcomes with JOACMEQ are shown in 
Table 5. Postoperatively, UE and LE functions in the N 
group significantly improved. In the DM group, LE func-
DM (-) DM (+)
Go od control of HbA1c 
after 1 yr




DMG group (n=12) DMB group (n=7)
79 Excluded
・66 Lack of data
・2 Died
・2  Suffered from lumbar spinal 
stenosis
・2 Suffered from spinal cord injury
・1  Suffered from cerebrovascular 
disease
・1 Cancel due to duct cancer
・ 1  Vitamin B12 lack disease 
revealed after surgery
・4 Never come at 1-year follow-up
N=61
DM group (n=19)
Fig. 1. Study flowchart. N group: a group without diabetes; DM group: 
a group with diabetes; DMG group: those with a good control of 
HbA1c after 1 year; DMB group: those with HbA1c deterioration after 
1 year. DM, diabetes mellitus; HbA1c, glycated hemoglobin.
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tion improved significantly, and UE function tended to-
ward improvement (p=0.051). There were no significant 
between-group differences for each parameter of the ef-
fective value.
6. Characteristics of the DMG and DMB groups
The ratio of males to females was higher in the DMG 
group than in the DMB group. There were no significant 
physical differences between the groups. Bowel and blad-
der disturbances were observed more frequently in the 
DMG group than in the DMB group (Table 6).
7.  Surgical outcomes based on the Japanese Orthopae-
dic Association scores between the DMG and DMB 
groups
JOA scores were significantly improved in both groups 
postoperatively (DMG group, p<0.03; DMB group, 
p<0.02). The RR was 30.1% in the DMG group and 19.8% 
in the DMB group. The RR did not significantly differ be-
tween the two groups (Table 7).
8.  Surgical outcomes based on the Japanese Orthopaedic 
Association Cervical Myelopathy Evaluation Ques-
tionnaire scores between the DMG and DMB groups
The DMG group exhibited less improvement in UE and 
LE surgical outcomes (Table 8).
9.  Changes in peripheral conduction time between the 
DMG and DMB groups
Preoperative PCT results are shown in Table 9. The PCT 
of the ulnar and tibial nerves did not significantly differ 
Table 2. Changes in FBG and HbA1c levels
Variable Preoperative
Postoperative period
1 wk (p-value)a) 4 wk (p-value)a) 1 yr (p-value)a)
N group (n=42)
FBG (mg/dL) 101.0±18.4   93.4±15.6 (0.00)    97.2±20.2 (0.29) 103.5±23.8 (0.60)
HbA1c (%)   5.6±0.4   5.6±0.4 (0.68)    5.5±0.4 (0.07)   5.6±0.3 (0.19)
DM group (n=19)
FBG (mg/dL) 155.1±48.9 115.4±21.9 (0.00) 114.8±29.2 (0.00) 149.9±50.9 (0.75)
HbA1c (%)   6.9±0.9   6.8±0.4 (0.19)   6.5±0.4 (0.04)   6.8±0.9 (0.06)
Values are presented as mean±standard deviation, unless otherwise stated. N group: a group without diabetes; DM group: a group with diabetes.
FBS, fasting blood glucose; HbA1c, glycated hemoglobin; DM, diabetes mellitus.
a)Compared with perioperative value.




Preoperative After 1 yr (p-value)
N group 10.9±2.8 13.5±4.8 (0.01) 40.1±39.0
DM group 10.8±7.5 12.9±5.0 (0.01) 26.3±34.4
p-value (N vs. DM group)    0.80 0.35   0.41
Values are presented as mean±standard deviation, unless otherwise stated. N group: a group without diabetes; DM group: a group with diabetes; 
p-value: preoperative vs. after 1 yr.
JOA, Japanese Orthopaedic Association; DM, diabetes mellitus.
Table 4. Correlations between hemoglobin A1c and recovery ratio 
levels
Variable Correlation coefficient p-value
Preoperative -0.15 0.26
At 1 wk -0.13 0.30
At 4 wk -0.02 0.85
At 1 yr -0.02 0.99
Pearson’s correlation coefficient.
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bladder Quality of life
N group
No. of patients 37 38 36 37 42
Score
Preoperative 67.5±30.8 64.6±23.3 44.6±27.3 66.2±18.2 45.3±16.0
At 1 yr 71.8±24.4 79.3±17.7 56.6±20.8 70.7±22.4 51.5±17.9
EV 4.3±28.8 14.7±22.2 12.1±23.7   4.5±20.3   6.2±18.1
p-value (preoperative vs. 1 yr) 0.36 <0.01 <0.01   0.18   0.31
DM group
No. of patients 12 18 19 16 19
Score
Preoperative 55.4±27.9 70.9±17.4 52.3±16.4 67.5±13.9 38.6±18.9
At 1 yr 50.0±26.0 82.7±18.1 68.3±26.0 72.1±17.0 48.9±18.1
EV   6.3±37.4 12.0±24.3 15.9±29.6   4.6±19.0 10.3±16.6
p-value (preoperative vs. 1 yr) 0.55   0.05 0.03   0.35   0.14
Values are presented as number or mean±standard deviation, unless otherwise stated. N group: a group without diabetes; DM group: a group with 
diabetes.
JOACMEQ, JOA Cervical Myelopathy Evaluation Questionnaire; DM, diabetes mellitus; EV, effective value.
Table 6. Characteristics and demographics of the DMG and DMB groups
Characteristic DMG group DMB group p-value
Age (yr)     66.4±10.3   74.1±10.1 0.11a)
Gender (male:female)   10:1   2:5 <0.01
Height (cm) 160.1±9.1 160.4±12.4 0.87a)
Body mass index (kg/m2)   23.3±3.3 23.2±4.2 0.93a)
Weight (kg)     60.5±12.4   59.4±11.2 0.70a)
CSM:OPLL     8:4   6:1 0.50b)
Peripheral conduction time (ms)
Ulna (right)   15.3±2.3 17.4±6.2 0.61a)
Ulna (left)   15.5±2.7 17.3±5.2 0.32a)
Tibia (right)   25.6±2.9 27.1±3.0 0.55a)
Tibia (left)   25.6±3.1 26.8±3.0 0.55a)
JOA   11.1±3.1 10.4±1.1 0.55a)
JOACMEQ
Cervical     64.6±32.2   59.3±28.3 0.70a)
Upper extremity     73.5±18.6   70.6±18.9 0.63a)
Lower extremity     54.8±27.8   48.1±28.4 0.55a)
Bowel & bladder     77.8±15.5   61.4±12.2 0.02a)
Quality of life     42.2±19.7   32.4±17.1 0.18
Values are presented as mean±standard deviation or number, unless otherwise stated. DMG group: those with a good control of HbA1c after 1 year; 
DMB group: those with HbA1c deterioration after 1 year.
DM, diabetes mellitus; CSM, cervical spondylotic myelopathy; OPLL, ossification of the posterior longitudinal ligament; JOA, Japanese Orthopaedic 
Association; JOACMEQ, JOA Cervical Myelopathy Evaluation Questionnaire; HbA1c, glycated hemoglobin.
a)By Mann-Whitney U-test. b)By Fisher's exact test.
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between the DMG and DMB groups.
Discussion
We evaluated surgical outcomes associated with CSM. 
Surgical outcomes based on JOA scores were not signifi-
cantly different between the N and DM groups. Further-
more, there were no significant differences relative to DM 
control. In fact, with respect to the RR with JOA, there 
were no significant differences between the N and DM 
groups and between the DMG and DMB groups with re-
spect to the presence of DM. Poor glycemic control affect-
ed CSM surgical outcomes as indicated by the JOACMEQ 
evaluation. We conclude that poor DM control impaired 
surgical outcomes in patients with CSM. Previous stud-
ies have reported that preoperative HbA1c levels affected 
recovery after CSM surgery [4,5]. DM is a risk factor for 
poor lumbar and cervical spinal surgery outcomes [12-15]. 
However, previous studies have focused only on the pres-
ence of DM, not on postoperative DM control.
DM affects outcomes of all types of spinal surgeries, yet 
most studies do not include postoperative DM control. 




Preoperative At 1 yr (p-value)
DMG group 11.1±3.1 13.6±2.1 (0.03) 30.1±48.0
DMB group 10.4±2.5 11.7±2.0 (0.02) 19.8±15.9
p-value (DMG vs. DMB) 0.55 0.06 0.44
Values are presented as mean±standard deviation or number, unless otherwise stated. DMG group: those with a good control of HbA1c after 1 year; 
DMB group: those with HbA1c deterioration after 1 year.
DM, diabetes mellitus; JOACMEQ, JOA Cervical Myelopathy Evaluation Questionnaire; JOA, Japanese Orthopaedic Association; HbA1c, glycated 
hemoglobin.








function Bowel & bladder Quality of life
DMG group
No. of patients 9 11 12 9 12
Score
Preoperative 52.8±28.3 71.1±17.4 54.8±27.8 72.2±14.0 42.2±19.7
At 1 yr 67.2±31.6 90.3±14.3 80.6±13.5 78.7±17.3 56.0±16.6
EV 14.4±42.1 19.6±23.7 26.2±31.0   6.4±15.7 13.8±16.3
p-value (preoperative vs. 1 yr)   0.34    0.02 0.01   0.28   0.02
DMB group
No. of patients 6 7 7 7 7
Score
Preoperative 52.5±24.0 70.6±18.9 48.1±25.3   61.4±112.2 32.4±17.1
At 1 yr 46.7±24.2 71.3±18.2 47.1±29.4 63.6±18.8 36.7±14.2
EV  -5.8±18.8   3.4±22.3   1.4±18.2   2.1±21.1   4.3±14.1
p-value (preoperative vs. 1 yr)   0.51    0.93   0.89   0.81  0.48
Values are presented as number or mean±standard deviation, unless otherwise stated. DMG group: those with a good control of HbA1c after 1 year; 
DMB group: those with HbA1c deterioration after 1 year.
DM, diabetes mellitus; JOA, Japanese Orthopaedic Association; JOACMEQ, JOA Cervical Myelopathy Evaluation Questionnaire; EV, effective value; 
HbA1c, glycated hemoglobin.
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The between-group differences in surgical outcomes in 
our study and in previous studies might be explained by 
conditional differences in patients with DM.
Diabetic neuropathy is one of the main factors in the 
diagnosis of patients with myelopathy. Nakanishi et al. 
[7] reported that the PCT of UE and LE were affected in 
patients with DM and CSM. This same study mentioned 
the possibility of DM causing peripheral nerve dysfunc-
tion, thereby affecting surgical outcomes. Generally, ini-
tial changes associated with diabetic neuropathy include 
extension of tibial F-wave latency [16,17]. In this study, no 
cases exhibited clear extension of F-wave latency. There 
were no significant differences between preoperative and 
postoperative PCTs in the DM group.
Patients with poor DM control often experience poorer 
recovery postoperatively than patients with good DM 
control. However, our results showed that peripheral dis-
orders associated with DM did not directly affect surgical 
outcomes.
We could not identify the mechanism(s) by which 
DM was associated with CSM; however, we consider two 
theories relevant. The first of these involves DM-linked 
microangiopathy. Microangiopathy interferes with nutri-
ent diffusion through the vertebral endplate, potentially 
leading to disk degeneration [12]. It is possible that DM 
angiopathy, therefore, interferes with nutrient delivery to 
other organs, including the spinal cord. Several studies 
mention possible spinal cord ischemia in patients with 
DM [18-20]. Mawad et al. [21] evaluated 24 patients who 
developed signs and symptoms of spinal cord ischemia or 
infarction following thoracoabdominal aortic aneurysm 
surgery using MRI. They determined that DM was a pre-
disposing risk factor for the development of postoperative 
spinal cord ischemia [21]. DM angiopathy might, there-
fore, affect surgical outcomes.
Our second theory involves DM myelopathy. Follow-
ing a post-mortem study, Reske-Nielsen and Lundbaek 
[22] have reported that patients with type 1 DM exhibited 
cranial nerve demyelination. There are other reports that 
describe a possible association between DM and central 
cord demyelination, axonal loss, and gliosis [23,24].
Selvarajah et al. [25] have investigated the relationship 
between spinal cord atrophy and neurophysiological as-
sessments among patients with DM by measuring the 
diameter of the spinal cord with MRI. Spinal cord atrophy 
is observed in patients with DM regardless of the pres-
ence or absence of diabetic peripheral neuropathies [25]. 
Although DM-related cervical cord atrophy is a potential 
factor, it is difficult to preoperatively measure the cord di-
ameter using MRI in patients with severe stenosis. In any 
case, poor control of DM appears to be a risk factor for 
microangiopathy and nervous system injury [26-28].
The 6.5-year Diabetes Control and Complication Trial 
in the United States divided patients with DM into two 
groups. The first group included patients receiving ‘typical’ 
DM therapy. The average HbA1c level in this group dur-
ing the study was approximately 9.0%. The other group 
of patients received strictly controlled DM therapy. The 
average HbA1c level in this group during the study was 
approximately 7.0%. The prevalence of DM neuropathy 
Table 9. Changes in PCT between the DMG and DMB groups
Variable
PCT (ms)
Ulna (right) Ulna (left) Tibia (right) Tibia (left)
DMG group
Preoperative 18.3±7.8 18.2±6.4 26.7±3.1 25.6±3.1
At 1 yr 16.0±3.0 16.7±3.2 24.9±3.7 26.5±2.7
p-value (preoperative vs. 1 yr)    0.14    0.18    0.12     0.18
DMB group
Preoperative 15.9±0.8 15.6±1.5 27.7±2.8 27.4±3.6
At 1 yr 16.0±1.1 15.8±1.5 27.5±3.1 27.5±3.2
p-value (preoperative vs. 1 yr)    0.78     0.47    0.61    0.86
Values are presented as mean±standard deviation or number, unless otherwise stated. DMG group: those with a good control of HbA1c after 1 year; 
DMB group: those with HbA1c deterioration after 1 year.
PCT, peripheral conduction time; DM, diabetes mellitus; HbA1c, glycated hemoglobin.
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was 13% among the patients receiving typical DM therapy 
and 5.0% among those receiving a stricter DM therapy at 
the end of this trial. DM control, therefore, appears to be 
important for preventing complications associated with 
DM, including neuropathy and angiopathy [29,30]. In 
this study, all the patients were under strict blood glucose 
control before surgery; after that, the patients who did not 
experience poorer blood glucose control exhibited good 
surgical outcomes. We believe that we can achieve good 
surgical outcomes in patients with CSM by enacting strict 
glycemic controls both preoperatively and postoperatively.
This study has several limitations. First, many patients 
were excluded because of a lack of data, particularly re-
garding HbA1c levels or PCT values at the 1-year follow-
up. Second, we investigated only FBG and HbA1c levels 
during the perioperative period and at 1 year postopera-
tively. We did not record glycemic control between these 
time points. Despite these limitations, we believe that 
strict control of DM is necessary for achieving good long-
term outcomes.
Conclusions
Postoperative improvement in CSM varies in association 
with control of DM symptoms during the preoperative 
and postoperative periods. We believe that poor glycemic 
control might prevent postoperative functional recovery 
of CSM.
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